Rhythm Pharmaceuticals Inc (RYTM) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Rhythm’s accelerating commercial traction while exposing inventory and regulatory risks that could affect near‑term profitability and long‑term pipeline value.

Key Takeaways

• Q4 product revenue $57.3M, 12% QoQ increase.
• Annual revenue $194.8M, 50% year‑over‑year growth.
• Inventory days on hand rose to 20, risking Q1 slowdown.
• SG&A up 10% driven by hypothalamic obesity launch prep.
• FDA mandates full 12‑month trial for bivomelanotide registration.

Pulse Analysis

Rhythm Pharmaceuticals posted a robust fourth‑quarter 2025, with product revenue climbing to $57.3 million—a 12 percent sequential gain and 37 percent year‑over‑year acceleration. Full‑year sales surged 50 percent to $194.8 million, reflecting expanding adoption of its MC4‑pathway therapy across the United States and an increasingly diverse international footprint. However, the company disclosed a negative inventory swing and a rise in days‑on‑hand to roughly 20, well above its 10‑15 day target, signaling a potential pull‑forward of shipments that could dampen first‑quarter sales. Management’s commentary underscores the need to balance commercial momentum with supply‑chain discipline.

The pipeline remains a central growth engine. Phase II data for bivomelanotide showed mean BMI reductions of 10.8 percent at 400 mg and 14.3 percent at 600 mg after forty weeks, rivaling setmelanotide outcomes. Yet the FDA has stipulated a full twelve‑month, double‑blind trial with a sample size comparable to the 142‑patient CEP‑1 study, extending the timeline and capital requirements for registration. Concurrently, Rhythm is poised for a U.S. launch of its acquired hypothalamic obesity (HO) indication, with a PDUFA target of March 20, while European and Japanese regulatory reviews progress, expanding the addressable rare‑obesity market.

Looking ahead, Rhythm forecasts 2026 non‑GAAP operating expenses between $385 million and $415 million, reflecting intensified investment in next‑generation MC4 agonists, the HO commercial rollout, and a Japanese operational build‑out. A cash pile of $389 million provides ample runway to fund these initiatives and sustain R&D momentum. The company’s expansion of IMCIVREE into more than 25 countries and a growing international team bolster its global reach, positioning Rhythm to capture a broader share of the rare‑genetic obesity segment that is increasingly competitive with GLP‑1 therapies. Investors will watch how the company navigates inventory pressures, regulatory hurdles, and scaling costs while leveraging its differentiated mechanism of action.